Many consumers feel powerless in the face of big industry’s interests. And the dominant view of economic regulators (influenced by Mancur Olson’s book The Logic of Collective Action, published in 1965) agrees with them. According to this... View Details
Filter Results:
(1,248)
Show Results For
- All HBS Web
(1,248)
- People (5)
- News (172)
- Research (929)
- Events (6)
- Multimedia (12)
- Faculty Publications (759)
Show Results For
- All HBS Web
(1,248)
- People (5)
- News (172)
- Research (929)
- Events (6)
- Multimedia (12)
- Faculty Publications (759)
- 20 Nov 2007
- First Look
First Look: November 20, 2007
discipline to nationalized banks. Pharmaceutical Regulation in the United States and Europe Author:Arthur Daemmrich Periodical:Focus on Law Studies 23, no 1 (fall 2007): 8-11 Read the full paper:... View Details
Keywords: Martha Lagace
Ranjay Gulati
Ranjay Gulati is the Paul R. Lawrence MBA Class of 1942 Professor of Business Administration and the former Unit Head of the Organizational Behavior Unit at Harvard Business School. His pathbreaking research, which focuses on unlocking organizational and unleashing... View Details
- 16 May 2023
- HBS Case
How KKR Got More by Giving Ownership to the Factory Floor: ‘My Kids Are Going to College!’
pharmaceuticals and technology. Rouen cautions that the model works best in fast-growing companies, where employees can receive a sizeable payout, and in situations where a sale in the not-too-distant future can translate into wealth.... View Details
Keywords: by Avery Forman
- Program
Strategy for Health Care Delivery—Virtual
for health care, or other payor organizations Leaders from pharmaceutical companies, medical device companies, or other health care supply companies—including startups and established firms Leaders in Virtual Learning This program... View Details
Robert S. Huckman
Robert Huckman is the Albert J. Weatherhead III Professor of Business Administration at Harvard Business School, the Howard Cox Faculty Chair of the HBS Healthcare Initiative, and the Unit Head for
V. Kasturi Rangan
Kash Rangan is the Malcolm P. McNair Professor of Marketing at the Harvard Business School. Formerly the chairman of the Marketing Department (1998-2002), he is now the co-chairman of the school's Social Enterprise Initiative. He has taught in a wide variety of MBA... View Details
Paul A. Gompers
Paul Gompers, Professor of Business Administration at the Harvard Business School, specializes in research on financial issues related to start-up, high growth, and newly public companies. Professor Gompers has an appointment in both the View Details
- 04 Jun 2013
- Working Paper Summaries
Prosocial Bonuses Increase Employee Satisfaction and Team Performance
Joshua D. Margolis
Joshua Margolis is James Dinan and Elizabeth Miller Professor of Business Administration and the Unit Head for the Organizational Behavior unit. He is also Faculty Chair of the Program for Leadership Development. His research and teaching revolve around leadership... View Details
- 28 Mar 2023
- Research & Ideas
The FDA’s Speedy Drug Approvals Are Safe: A Win-Win for Patients and Pharma Innovation
Wiener Professor of Public Policy and Director of Health Policy Research at the Harvard Kennedy School of Government. Jennifer Kao of the University of California, Los Angeles and the FDA’s Kathleen Miller are also coauthors. Speeding innovation without compromising... View Details
- July 2023
- Case
HealthVerity: Real World Data and Evidence
By: Satish Tadikonda
Andrew Kress (CEO and founder) and his team had built a promising marketplace business at HealthVerity serving its core market in healthcare, with a focus on pharmaceutical R&D and services. Thus far, HealthVerity’s products had been unique to the pharma and pharma... View Details
Tadikonda, Satish. "HealthVerity: Real World Data and Evidence." Harvard Business School Case 824-019, July 2023.
- December 2018
- Case
Corporate Transformation at Merck KGaA, Darmstadt, Germany
By: Joseph B. Fuller, Amy C. Edmondson, Daniela Beyersdorfer and Tonia Labruyere
When Stefan Oschmann became CEO and chairman of the executive board of Merck KGaA, Darmstadt, Germany, in 2016, the company had started its transformation from a mid-tier traditional German industry player to a global modern science and technology player. The... View Details
Keywords: Corporate Governance With Family Ownership; Transformation; Change Management; Restructuring; Corporate Governance; Family Ownership
Fuller, Joseph B., Amy C. Edmondson, Daniela Beyersdorfer, and Tonia Labruyere. "Corporate Transformation at Merck KGaA, Darmstadt, Germany." Harvard Business School Case 319-072, December 2018.
Malcolm P. Baker
Malcolm Baker is the Robert G. Kirby Professor of Business Administration at the Harvard Business School, where he teaches the required course in finance and a short immersive program on investing in life sciences.
His research is in the... View Details
- March 2023 (Revised June 2025)
- Case
Close Concerns: Diabetes Research and Advocacy
By: Regina E. Herzlinger and Brian L. Walker
Diagnosed with diabetes at the age of 18, Kelly Close understood the importance of balancing consistency and iteration. This principle had also informed her professional work, which started with a rapid promotion from financial analyst at Goldman Sachs to an analyst... View Details
Keywords: Diabetes; Health; Health Care; Health Care And Treatment; Health Care Outcomes; Health Care Industry; Knowledge Dissemination; Outcome or Result; Equality and Inequality; Business Model; Entrepreneurship
Herzlinger, Regina E., and Brian L. Walker. "Close Concerns: Diabetes Research and Advocacy." Harvard Business School Case 323-047, March 2023. (Revised June 2025.)
- 09 Feb 2024
- HBS Case
Slim Chance: Drugs Will Reshape the Weight Loss Industry, But Habit Change Might Be Elusive
Year after year, millions of people make a new year’s resolution to lose weight. But because success traditionally depends on making major lifestyle changes, like eating healthier and exercising more, many people fall short of their fitness goals. Yet in 2024, more... View Details
Gary P. Pisano
Gary Pisano is the Harry E. Figgie, Jr. Professor of Business Administration at the Harvard Business School where he has been on the faculty since 1988. From 2018-2023, Pisano was Harvard Business School’s Senior Associate Dean for Faculty Promotion and... View Details
- 21 Feb 2018
- Research & Ideas
When a Competitor Abandons the Market, Should You Advance or Retreat?
Terminations: Learning from Competitors’ R&D Failures, Krieger explores how pharmaceutical companies choose to react strategically when a competitor exits the market during the development stage. These companies may decide further... View Details
- Web
Organizational Behavior - Faculty & Research
Transformation ; Pharmaceutical Industry ; Biotechnology Industry ; Health Industry ; United States ; Asia ; Europe ; Latin America Citation Related Hill, Linda A., and Lydia Begag. "Michael Ku and Global Clinical Supply at Pfizer Inc.:... View Details
- 02 Aug 2011
- First Look
First Look: August 2
pharmaceutical and skin care company. During World War I the expropriation of its brands and trademarks revealed its vulnerability to political risk. Following the advent of the Nazi regime in 1933, the largely Jewish owned and managed... View Details
Keywords: Sean Silverthorne